Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abivax SA
Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.
With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.